SVB Leerink Maintains Outperform on Inari Medical, Raises Price Target to $120
SVB Leerink analyst Danielle Antalffy maintains Inari Medical (NASDAQ:NARI) with a Outperform and raises the price target from $110 to $120.
Inari Medical Q3 EPS $(0.06) Beats $(0.11) Estimate, Sales $72.92M Beat $63.03M Estimate
Inari Medical (NASDAQ:NARI) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.11) by 45.45 percent. This is a 150 percent decrease over earnings of $0.12 per share from the
The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data
Here's a roundup of top developments in the biotech space over the last 24 hours:
Earnings Scheduled For November 9, 2021
Companies Reporting Before The Bell
• Imara (NASDAQ:IMRA) is projected to report earnings for its third quarter.
• KT (NYSE:KT) is projected to report earnings for its third quarter.
Inari Medical Announces 6-month FLASH Registry Interim Data From 500 Real-World PE Patients In Enrolled In FlowTriever Outcomes Registry
Inari Medical, Inc. (NASDAQ:NARI) ("Inari") a medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, today announced positive acute
President And CEO Of Inari Medical Makes $2.4M Sale
William Hoffman, President And CEO at Inari Medical (NASDAQ:NARI), made a large insider sell on October 7, according to a new SEC filing.
66 Biggest Movers From Yesterday
Gainers
Rani Therapeutics Holdings, Inc. (NASDAQ: RANI) shares jumped 50.5% to close at $20.74 on Wednesday. The company, last month, priced its IPO at $11 per share.
Inari Medical Plunged 15% After Mixed Q2 Earnings, Lifting FY21 Sales Guidance
Inari Medical Inc’s (NASDAQ:NARI) Q2 revenue was $63.5 million, more than doubled from $25.4 million in Q2 FY20, beating the…
48 Stocks Moving In Wednesday’s Mid-Day Session
Gainers
Rani Therapeutics Holdings, Inc. (NASDAQ: RANI) gained 82% to $25.19. The company, last month, priced its IPO at $11 per share.